Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.64 |
| ▸ | HTR2A | P28223 | 5/20 | 0.64 |
| ▸ | HRH1 | P35367 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.64 |
| ▸ | HTR2C | P28335 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.64 |
| ▸ | DRD3 | P35462 | 4/20 | 0.64 |
| ▸ | HTR2B | P41595 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.64 |
| ▸ | HRH2 | P25021 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tofenacin SCHEMBL637494 | 0.98 | LMNA (0.65) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| SCHEMBL4667597 | 0.87 | CYP2D6 (0.76) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| SCHEMBL3333230 | 0.85 | SIGMAR1 (0.68) | CYP2D6SLC6A2HTR2AHRH1CHRM1 | |
| Hydrochloric Acid SCHEMBL28100967 | 0.83 | HTT (0.69) | CYP2D6SLC6A2HTR2AHRH1CHRM1 | |
| SCHEMBL25375446 | 0.81 | CYP2D6 (0.68) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| SCHEMBL4669319 | 0.81 | CYP2D6 (0.68) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| SCHEMBL8105789 | 0.78 | CYP2D6 (0.64) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| Orphenadrine SCHEMBL119471 | 0.78 | SLC6A2 (1.00) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| Orphenadrine SCHEMBL28727 | 0.78 | SLC6A2 (1.00) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 | |
| Orphenadrine SCHEMBL29359844 | 0.78 | SLC6A2 (1.00) | CYP2D6SLC6A2HTR2AHRH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2359 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496300-B2 | Methods of treating acute depression and anxiety | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| CN-119072304-A | Neuroactive steroids for the treatment of CNS related disorders | 萨奇治疗股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| CN-114869838-A | Soothing and moisturizing composition and preparation method and application thereof | 广州市科能化妆品科研有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002080708-A2 | A SMOKER'S REQUISITE | ENSLIN GEORGE FREDERICK (ZA) | 2002-10-17 | — | — | WO | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |